Article

Program-level and contextual-level determinants of low-median CD4(+) cell count in cohorts of persons initiating ART in eight sub-Saharan African countries

International Center for AIDS Care and Treatment Programs, Columbia University Mailman School of Public Health, New York, New York, USA.
AIDS (London, England) (Impact Factor: 6.56). 07/2011; 25(12):1523-33. DOI: 10.1097/QAD.0b013e32834811b2
Source: PubMed

ABSTRACT In sub-Saharan Africa, many patients initiate antiretroviral therapy (ART) at CD4 cell counts much lower than those recommended in national guidelines. We examined program-level and contextual-level factors associated with low median CD4 cell count at ART initiation in populations initiating ART.
Multilevel analysis of aggregate and program-level service delivery data.
We examined data on 1690 cohorts of patients initiating ART during 2004-2008 in eight sub-Saharan African countries. Cohorts with median CD4 less than 111 cells/μl (the lowest quartile) were classified as having low median CD4 cell count at ART initiation. Cohort information was combined with time-updated program-level data and subnational contextual-level data, and analyzed using multilevel models.
The 1690 cohorts had median CD4 cell count of 136 cells/μl and included 121,504 patients initiating ART at 267 clinics. Program-level factors associated with low cohort median CD4 cell count included urban setting [adjusted odds ratio (AOR) 2.1; 95% confidence interval (CI) 1.3-3.3], lower provider-to-patient ratio (AOR 2.2; 95% CI 1.3-4.0), no PMTCT program (AOR 3.6; 95% CI 1.0-12.8), outreach services for ART patients only vs. both pre-ART and ART patients (AOR 2.4; 95% CI 1.5-3.9), fewer vs. more adherence support services (AOR 1.6; 95% CI 1.0-2.5), and smaller cohort size (AOR 2.5; 95% CI 1.4-4.5). Contextual-level factors associated with low cohort median CD4 cell count included initiating ART in areas where a lower proportion of the population heard of AIDS, tested for HIV recently, and a higher proportion believed 'limiting themselves to one HIV-uninfected sexual partner reduces HIV risk'.
Determinants of CD4 cell count at ART initiation in populations initiating ART operate at multiple levels. Structural interventions targeting points upstream from ART initiation along the continuum from infection to diagnosis to care engagement are needed.

Download full-text

Full-text

Available from: Denis Nash, Jul 19, 2015
0 Followers
 · 
148 Views
  • Source
    • "Although some 5 million patients are currently accessing antiretroviral therapy (ART) globally (WHO/UNAIDS/ UNICEF 2010), late presentation for ART, as represented by persistently low CD4 counts at ART initiation, continues to be the norm in many parts of the world (Rosen et al. 2007; Cornell et al. 2010; Fox & Rosen 2010; Nash et al. 2011). This phenomenon prevails even where widespread HIV testing is available, due in part to failure of patients who are not yet eligible for treatment when diagnosed (Bassett et al. 2009, 2010; Micek et al. 2009; Larson et al. 2010a,b; Losina et al. 2010; Tayler-Smith et al. 2010) to enrol and remain in pre-ART care and failure to initiate treatment promptly among those who are already ART eligible at HIV diagnosis (Ingle et al. 2010). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Objectif: Proposer des définitions standard pratiques pour le report des rétentions dans les soins pré‐ART.Méthode: Définitions tablée sur trois stades: Stade 1, du test VIH‐positif à l’évaluation initiale de l’éligibilité pour l’ART; Stade 2, de l’évaluation initiale à l’éligibilité pour l’ART et Stade 3, de l’éligibilitéà l’initiation de l’ART. Pour chaque stade, les résultats négatifs comprennent le décès, les perdus de vue, ou le fait de ne pas être retenu.Résultats: Rétention dans le stade 1: la proportion de patients qui ont terminé l’évaluation initiale de l’éligibilité pour l’ART dans les 3 mois du dépistage du VIH, avec les reports des résultats de la cohorte à 3 et 12 mois après le dépistage du VIH. Les patients terminant le stade 1, éligibles pour l’ART, passent directement à l’étape 3. Rétention dans le stade 2: la proportion de patients qui soit terminent toutes les possibles réévaluations pour l’éligibilitéà l’ART dans les 6 mois du calendrier de visite standard du site, soit ont eu une évaluation endéans 1 an de la date du report et n’étaient pas admissibles pour l’ART à la dernière évaluation. La rétention devrait être rapportée à intervalles de 12 mois. Rétention dans le stade 3: Initiation de l’ART (i.e. ART administré) dans les 3 mois de l’éligibilité pour l’ART, avec des reports à 3 mois après l’éligibilité et avec des intervalles de 3 mois par la suite.Conclusion: Si la rétention pré‐ART doit être améliorée, une terminologie cohérente est nécessaire pour la collecte des données, la mesure et le report des résultats, et la comparaison des résultats entre les programmes et les pays. Les définitions que nous proposons offrent une stratégie pour améliorer la cohérence et la comparabilité des futurs rapports.
    Tropical Medicine & International Health 08/2012; 17(10). DOI:10.1111/j.1365-3156.2012.03055.x · 2.30 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To utilize routinely collected service delivery data from HIV care and treatment clinics in Mozambique to describe the patient population and programmatic outcomes from 2003 to 2009. Data from patient charts were entered into an electronic database at 28 clinics in 5 Mozambican provinces. Patients' characteristics at enrollment in HIV care and at antiretroviral therapy (ART) initiation were examined. We calculated a corrected 12-month mortality estimate using a recently developed nomogram for sub-Saharan African ART patients. A total of 154,188 HIV-infected individuals (10,164 children <15 years old) were enrolled in HIV care services between 2003 and 2009. Of the 51,269 (36%) adults who started ART, 35% initiated ART with CD4 count <100 cells per microliter and 14.4% with World Health Organization stage IV. Just more than 10% (10.5%) of women were documented to be pregnant at enrollment. One-third of the 3,745 (37%) children who initiated ART were <2 years old, and 53% of those <5 years initiated ART severely immunosuppressed (CD4% <15%). Thirty-five percent of all children and 30% of those initiating ART met the definition of severe malnourishment (weight-for-age Z score <-3). Among those who initiated ART, the median estimated 12-month mortality rate across sites was 13.1% (interquartile range: 11.5%-16.0%) and 13.5% (interquartile range: 11.4%-17.4%) for adults and children, respectively. A substantial number of HIV-infected patients have been enrolled in HIV care and initiated on ART, with many patients having advanced HIV disease. With the release of new guidelines for ART use for adults, pregnant women, and children, extensive efforts are needed to ensure more timely initiation of ART.
    JAIDS Journal of Acquired Immune Deficiency Syndromes 06/2011; 58(3):e75-86. DOI:10.1097/QAI.0b013e31822ac0a9 · 4.39 Impact Factor
  • AIDS (London, England) 07/2011; 25(12):1547-8. DOI:10.1097/QAD.0b013e32834940b3 · 6.56 Impact Factor
Show more